


# XI Monographic Conference



## Nano and Biotechnology in Drug Discovery & Development

Málaga 16th-17th October 2014





# XI Monographic Conference of the SEQT

## Nano and Biotechnology in Drug Discovery & Development

Málaga 16th-17th October 2014

### Programme

#### Day 1: Thursday 16<sup>th</sup> October

<b>13:30</b>	Departure of Coach from hotel Monte Málaga to Bionand
<b>14:00-15:00</b>	Catered Reception
<b>15:00-15:30</b>	Opening remarks
<b>15:30-16:30</b>	Inaugural Lecture Targeting oncogene-induced replication stress for cancer therapy Oscar Fernández Capetillo Centro Nacional de Investigaciones Oncológicas
<b>16:30-17:00</b>	Personalized Cancer Nanomedicine Simó Schwartz Centro Investigación en Bioquímica y Biol. Mol. para Nanomedicina-Vall d'Hebron
<b>17:00-17:30</b>	Coffee break
<b>17:30-18:00</b>	Cardio-reparative therapies for the treatment of ischemic heart disease Luis Rodríguez Borlado Coretherapix. Grupo Genetrix
<b>18:00-18:30</b>	The senescence associated secretory phenotype (SASP): friend and foe Jesus Gil Imperial College London
<b>18:40</b>	Departure of coach back to Hotel (if not attending the SEQT Assembly meeting)
<b>18:40-19:40</b>	SEQT Assembly meeting
<b>19:45</b>	Departure of coach back to hotel Monte Málaga
<b>21:15</b>	Departure of coach from hotel Monte Málaga to Gala Dinner
<b>21:30</b>	Gala Dinner Restaurant Limonar 40


## Day 2: Friday 17<sup>th</sup> October

---

<b>9:15</b>	Departure of coach from hotel Monte Málaga to Bionand
<b>10:00-11:00</b>	Keynote Lecture <b>Targeting cancer's engines, not its drivers</b> Gerard Evan Department of Biochemistry, University of Cambridge
<b>11:00-11:30</b>	Talk to be announced Luis Paz-Ares Instituto Biomedicina de Sevilla
<b>11:30-12:00</b>	Coffee break
<b>12:00-12:30</b>	Gated materials for controlled delivery. Potential biomedical applications Ramón Martínez Máñez Instituto de Química Molecular Aplicada. Universidad Politécnica de Valencia
<b>12:30-13:00</b>	Drug and Cell Delivery Systems for Cardiac Repair Felipe Prósper Centro de Investigación Médica Aplicada. Universidad de Navarra
<b>13:00-13:30</b>	Efficacy of edelfosine-loaded lipid nanoparticles against lymphoma María Blanco Prieto Departamento de Farmacia y Tecnología Farmacéutica. Universidad de Navarra
<b>13:30-15:00</b>	Catered lunch
<b>15:00-15:30</b>	Dendrimers for diagnosis of IgE-mediated drug allergic reactions Maribel Montañez BIONAND/IBIMA
<b>15:30-16:00</b>	Toxicometabolomics approach for early detection of potential hepatotoxicity of new drug candidates José Vicente Castell Instituto de Investigación Sanitaria La Fe
<b>16:00-16:30</b>	Coffee break
<b>16:30-17:30</b>	Closing Lecture <b>Interaction of colloidal particles with cells</b> Wolfgang Parak Phillips University Marburg/CIC Biomagune
<b>17:30-18:00</b>	Concluding remarks
<b>18:00</b>	Departure of coach back to hotel Monte Málaga

---

## Conference Speakers



### **Óscar Fernández-Capetillo. CNIO.**

Óscar (Bilbao, 1974) obtained his PhD from the Universidad del País Vasco working on the role of E2F transcription factors with Ana Zubiaga. He next joined the laboratory of André Nussenzweig at the National Cancer Institute (USA), where he started to work on the cellular responses to DNA damage, investigating the role of the histone variant H2AX. In 2005 he joined the CNIO to lead the Genomic Instability Group where his research focuses on replication stress as a driver of genomic instability in cancer and ageing, and to explore if tumor-associated genomic instability can be exploited for cancer therapy.



### **Simó Schwartz. CIBMM-Nanomedicine-Vall d'Hebron.**

Dr Simó Schwartz Jr (1967, Barcelona) obtained his Medical degree in 1991 at the Faculty of Medicine of the Autonomous University of Barcelona, where he also got his PhD in 1996 working on oncogenic signalling pathways in prostate cancer. He was a research fellow in the New York Univ. Medical Center in 1993 and postdoctoral research at the Burnham Institute for Biomedical Research in San Diego, USA, in 1996. In 2000 he was appointed as Team leader at the Molecular Biology and Biochemistry Research Center for Nanomedicine (CIBBIM-Nanomedicine) of the Vall d'Hebron University Hospital in Barcelona, which is focused on the research of new biomedical nanotechnology-based applications. In particular, new drug delivery systems, image based diagnostic systems and preclinical validation of therapeutic conjugates and bio-nanosensors, mainly in the areas of oncology and rare diseases. In 2010 he was appointed as Director and Board member of the CIBBIM-Nanomedicine and also member of the Science Advisory Board of the Vall d'Hebron Research Institute (VHIR).



### **Luis Rodríguez Borlado. Coretherapix. Grupo Genetrix.**

Luis R.-Borlado has a PhD in Biochemistry and Molecular Biology from the University Autónoma of Madrid with the study of molecular bases of immune system development. After developing a scientific career in academic laboratories in Spain and The Netherlands developing high-throughput screenings to identify new therapeutic cancer targets, he joined Coretherapix in 2008 (a company belonging to the Genetrix group). At Coretherapix he has been responsible for designing the essential cell characterization and pre-clinical studies enabling the filing of the IND corresponding to Coretherapix's first candidate product, a task he has led in his role of Scientific Director.



### **Jesus Gil. MRC-CSC. Imperial College London.**

Jesús obtained his PhD, working in Mariano Esteban's lab at the CNB-CSIC in 2000. He moved to work in David Beach's lab screening for genes bypassing senescence, identifying the Polycomb CBX7. He continued investigating how CBX7 regulates the INK4/ARF locus with Gordon Peters and Scott Lowe. Since 2005 he leads the Cell Proliferation Group at the MRC Clinical Sciences Centre, Imperial College London. He is interested in the regulation and function of senescence. Jesús was named an EMBO Young Investigator in (2008) and obtained the EACR Cancer researcher Award 'highly commended' (2011). He is a Professor at Imperial College (2013).



**Gerard Evan. Dept. Biochemistry. University of Cambridge.**

Gerard Evan received his BA in Biochemistry from the University of Oxford and his Ph.D. in Molecular Immunology from the MRC Laboratory of Molecular Biology at the University of Cambridge. He was then a Medical Research Council Post-Doctoral Fellow and, later, a Science and Engineering Research Council Fellow in the laboratory of J. Michael Bishop at the University of California, San Francisco (UCSF). He then returned to the UK to become an Assistant Member of the Cambridge Branch of the Ludwig Institute for Cancer Research and a Research Fellow of Downing College, University of Cambridge. In 1988 he joined the Imperial Cancer Research Fund (ICRF) Laboratories in London as a Senior Scientist (1988-90) and then Principal Scientist from 1990-1999. In 1996 he was awarded the Royal Society's Napier Professor of Cancer Research. He was appointed to the Gerson and Barbara Bass Bakar Distinguished Professor of Cancer Biology at the U. of California, San Francisco in 1999 and in 2009 moved to the UK to take up the Sir William Dunn chair of Biochemistry in the University of Cambridge. Gerard is a member of EMBO, a Fellow of the UK Academy of Medical Sciences and the Royal Society.



**Luis Paz-Ares. IBIS.**

Luis Paz-Ares heads the Oncology Department at the University Hospital Virgen del Rocío in Seville since 2007. He holds an MD from Universidad Autónoma in Madrid, where he also obtained his PhD on Medical Oncology in 1993. He obtained a Masters Degree in Clinical Pharmacology at Glasgow University in 1995, and another one on Administration of Clinical Units at UNED University in Madrid in 2005. He became Professor of Medical Oncology at Universidad de Sevilla and deputy director of the Biomedicine Institute of Seville (IBIS). Dr. Paz-Ares has authored more than 150 publications, with an IF index of 10.2. Currently he is Principal Investigator in 10 funded projects, and directs or collaborates in more than 50 clinical trials.



**Ramón Martínez Máñez. IQMA-IPV.**

Ramón Martínez-Mañez graduated in Chemistry at the University of Valencia in 1986, and he received his Ph.D. in 1990 at the same university. After a postdoctoral period at Cambridge (UK), he joined the Department of Chemistry at the UPV. He became a full professor in 2002. Currently he is director of the Research Institute IDM at the UPV. He is coauthor in more than 270 research publications and 12 patents. His main areas of interest fall in the field of chromo-fluorogenic probes and gated delivery systems.



**Felipe Prósper. CIMA-Universidad de Navarra.**

Dr Felipe Prósper received his MD degree at the University of Navarra in 1989 and completed his training in Hematology and Oncology at the University of Minnesota between 1994-97. His current position is Director of Cell Therapy and co-director of Hematology at the Clínica Universidad de Navarra where he is responsible for the Cell Therapy program. His research is mainly focus on the biology of stem cells and their application for human diseases. Specific research areas of interest are the use of stem cells for cardiovascular diseases and the role of epigenetics in hematological malignancies. The group lead by Dr Prósper has also an interest in the clinical application of these therapies and has recently developed several clinical trials using mesenchymal stem cells as well as other progenitor cells in diverse pathologies. Dr Prósper has published more than 200 articles in peer review international journals and received several awards for his research. He reviews for several top-rank publications such as Blood, Circulation, Journal of Clinical Investigation among others.



**María Blanco Prieto. Dept. Farmacia y Tecnología Farmacéutica.**

**Universidad de Navarra.** María Blanco-Prieto received her Pharmacy Degree from the University of Santiago de Compostela, followed by a PhD in Pharmaceutical Sciences from the University of Paris-Sud. She completed a post-doctoral training at the Swiss Federal Institute of Technology (ETH), Zürich, and then joined the University of Navarra where presently she is full professor of Biopharmaceutics and Pharmaceutical Technology. Her research lay in the field of biomaterials and advanced drug carrier systems including the design and the

development of micro- and nanoscale carriers, their biological evaluation in in vitro cell and also their pharmacokinetic and dynamic impact in vivo. She is the author of more than 100 scientific articles and book chapters, 2 editorials, 5 patents, and more than 130 presentations at scientific conferences.



**Maribel Montañez. BIONAND-IBIMA.**

M<sup>a</sup> Isabel Montañez received her PhD in Chemistry (2007) from the University of Málaga working on the synthesis and study of antigenic determinants of cephalosporins and dendrimeric antigens of penicillins, for detection of IgE specific to  $\beta$ -Lactams. She completed a postdoctoral training at Royal Institute of Technology (Stockholm), working mainly in projects related with efficient and versatile design of complex macromolecules via click chemistry for advanced biomedical applications. In 2010 she joined the research group of Allergic Diseases

led by Dr. Blanca at IBIMA/BIONAND. Her current position is as IEF-MC Postdoctoral fellow, working on the improvement of in vitro test for detecting allergy against drugs by using complex macromolecule architectures.



**José Vicente Castell. IIS-La Fe.**

PhD in Biochemistry and MD in Medical Biochemistry, Graduate in Pharmacy. Postdoctoral at the ETH-Zürich and Max-Planck Institut Göttingen. Chair of Medical Biochemistry and Molecular Biology at the Medical School in Valencia where he also reads a postgraduate course on Molecular Toxicology. Director of the Medical Research Center of the University Hospital La Fe (Valencia) and head of the Unit of Experimental Hepatology Pharmaceutical of the European Federation of Pharmaceutical Industries (Heidelberg 1990) for the development of

(1990) for developing cultured human hepatocytes to investigate the hepatotoxic risk of new drugs to man. His major research interests include: drug metabolism and hepatotoxicity, cell therapy with human hepatocytes and PSC-derived hepatocytes, topics in which he has authored more than 350 papers.



**Wolfgang Parak. Phillips University Marburg/CIC Biomagune.**


Wolfgang Parak graduate in Physics at the Technische Universität München, Germany and obtained his PhD at the Ludwig Maximilians Universität München, Germany in the group of Prof. Dr. Hermann Gaub in 1999. From 2000 – 2002 he was PostDoctoral Fellow at the Chemistry Department of the University of California, Berkeley, CA, USA in the group of Prof. Dr. Paul Alivisatos. From 2002 – 2007 he was Assistant and Associate Professor at the Ludwig Maximilians Universität München, Germany. Since 2007 he is Full Professor at the Physics Department of

the Philipps Universität Marburg, Germany. Since 2013 he also has an additional group at CIC Biomagune, San Sebastian, Spain. Wolfgang Parak is Associate Editor of ACS Nano.

This conference would not be possible  
without the generous support of our sponsors








<http://www.seqt-conference.es/>

# XI Monographic Conference






## Nano and Biotechnology in Drug Discovery & Development

Málaga 16th-17th October 2014



# XI Monographic Conference

Málaga 16<sup>th</sup>-17<sup>th</sup> October 2014



OCDPNAEISA**SEQT**WLLIAPATGOFT SGRID  
GSVMLTVPPA**SEQT**LSIGTD NGRLL  
GSVMLTVPPA**SEQT**TRLMSGRS DAPATGO  
HTTRLKRVG**SEQT**LTVPALLNALSLGTTCT  
DNGRLIVEP**SEQT**OELEVENTHYSLLAEERIDN  
LDAPATGO**SEQT**HTTRLKRVGGSVMLTVPPALLNALSLGEP  
LGTDNEV**SEQT**DNGRLIMONOGRAPHICIOYSLAELLAL  
NAEISA**SEQT**WLDAPATGOEBIMHTTRLKRVGMSGRS  
LTVPPA**SEQT**LSLGTDNERAVCONFERENCEGMVIDN  
YSLAE**SEQT**CDPNAEISAEEREWLDAPATGOIVEP

## Nano and Biotechnology in Drug Discovery & Development

### Committees

Scientific

Guillermo de la Cueva (Bionand, Málaga)  
Antoni Torrens (Esteve, Barcelona)  
Antonio Pineda (CIPF, Valencia)  
Javier Fernández (Janssen, Toledo)  
M. Pilar Marco (IQAC-CSIC, Barcelona)

Organizing

Guillermo de la Cueva (Bionand, Málaga)  
Javier Rojo (IIQ-CSIC, Sevilla)  
Beatriz de Pascual-Teresa (USP-CEU, Madrid)  
Ana Castro (IQM-CSIC, Madrid)  
Manuel Cano (Bionand, Málaga)  
Rebeca Núñez (Bionand, Málaga)

### Speakers

Oscar Fernández Capetillo (CNIO)  
Gerard Evan (University of Cambridge)  
Wolfgang Parak (Philipps University Marburg/  
CIC Biomagune)  
Simó Schwartz (CIBBIM-Vall d'Hebron)  
Luis Paz-Ares (IBIS)  
Jesús Gil (Imperial College London)  
María Blanco Prieto (Universidad de Navarra)  
José Vicente Castell (IIS La Fe)  
Ramón Martínez Máñez (IQMA/UPV)  
Felipe Prósper (CIMA)  
Luis Rodríguez Borlado (Coretherapix)  
Maribel Montañez (BIONAND/IBIMA)

<http://www.seqt-conference.es/>

